Independent study conducted at boston children's hospital, harvard medical school, shows potential utility of jaguar health's crofelemer for treatment of mvid, a rare childhood disease

Mvid, for which there are no approved drug treatments, is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea crofelemer has been granted orphan drug designation by the fda and the european medicines agency for mvid, and the company's investigational new drug application for crofelemer for treatment of mvid is now activated by the fda san francisco, ca / accesswire / october 19, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that an independent, investigator-initiated study evaluating the efficacy of crofelemer, the company's plant-based prescription drug, for the treatment of microvillus inclusion disease (mvid) has been published in the journal of clinical investigation (jci), a peer-reviewed medical journal covering biomedical research. the results of this in vitro study demonstrate that crofelemer has the clinical potential for symptomatic therapy and electrolyte and fluid management in mvid patients.
JAGX Ratings Summary
JAGX Quant Ranking